The use of tranexamic acid (TXA) has markedly increased since the results of the CRASH-II trial were published. In addition to its use in trauma, TXA has been evaluated and used in numerous other conditions, including post-partum hemorrhage and epistaxis. Recently, the HALT-IT Trial was published online in the Lancet, which evaluated the use of TXA in patients with acute gastrointestinal bleeding. In this podcast we discuss the HALT-IT Trial and its implications for clinical practice.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
To say that 2020 has been a challenging year would be a gross understatement. The courage and determination that all healthcare providers have shown...
Emergency department (ED) visits for critically ill patients has nearly doubled over the past decade. Unfortunately, ED boarding of critically ill patients awaiting ICU...
Hyponatremia is one of the most common electrolyte disorders encountered in emergency medicine and critical care. Patients with hyponatremic encephalopathy represent a severe form...
